SlideShare une entreprise Scribd logo
1  sur  5
News
                                                           For Immediate Release

Contact:     Gary Gatyas
             IMS Institute for Healthcare Informatics
             (610) 244-2600
             ggatyas@us.imshealth.com

     IMS Study Forecasts Rebound in Global Spending on
      Medicines, Reaching Nearly $1.2 Trillion By 2016
 Spending in Pharmerging Markets to Nearly Double while Health Systems
  in Developed Countries Benefit from Historically Low Spending Growth


PARSIPPANY, NJ, July 12, 2012 – Following several years of slowing growth, the

global market for medicines is poised to rebound from an expected low point of 3-4

percent growth in 2012 to 5-7 percent in 2016, according to a new forecast issued

by the IMS Institute for Healthcare Informatics.

      The report, The Global Use of Medicines: Outlook through 2016, found that

annual global spending on medicines will rise from $956 billion in 2011 to nearly

$1.2 trillion in 2016, representing a compound annual growth rate of 3-6 percent.

Growth in annual global spending is forecast to more than double by 2016 to as

much as $70 billion, up from a $30 billion pace this year, driven by volume

increases in the pharmerging markets and an uptick in spending in developed

nations.

      Additionally, patent expiries, which will peak in 2012, as well as increased

cost-containment actions by payers, will constrain branded medicine spending

growth through 2016, at 0-3 percent. Developed markets are expected to
2

experience their lowest annual growth this year, at less than 1 percent or $3 billion,

and then rebound to $18-20 billion in annual growth in the 2014-16 period.

      “As health systems around the world grapple with macroeconomic pressures

and the demand for expanded access and improved outcomes, medicines will play

an even more vital role in patient care over the next five years,” says Murray

Aitken, executive director, IMS Institute for Healthcare Informatics. “The trillion-

dollar spending on medicines we forecast for 2016 represents a rebound in growth

that will accentuate the challenges of access and affordability facing those who

consume and pay for healthcare around the world.”

      In its latest analysis, the IMS Institute identifies the following dynamics:

      •   Health systems in developed economies will experience slow growth
          in medicine spending. Spending on medicines in developed nations will
          increase by a total of $60-70 billion from 2011 to 2016, following an increase
          of $104 billion between 2006 and 2011. Despite the highest number of
          patent expiries in history, spending in the U.S. will grow by $35-45 billion
          over the next five years, representing an average annual growth rate of 1-4
          percent, as newer medicines that address unmet needs are introduced and
          patient access expands in 2014 due to implementation of the Affordable Care
          Act. In Europe, growth will be in the -1 to 2 percent range due to significant
          austerity programs and healthcare cost-containment initiatives. The Japanese
          market for medicines is forecast to grow 1-4 percent annually through 2016,
          slightly lower than the rate during the prior five years and reflecting biennial
          price cuts scheduled for 2012, 2014 and 2016. Overall, patent expiries in
          developed markets will yield a five-year “patent dividend” of $106 billion,
          reflecting reduced brand spending of $127 billion offset by $21 billion in
          higher generics spending.
3

•   Health systems in pharmerging markets will nearly double their
    medicine spending in five years. Annual spending on medicines in the
    pharmerging markets will increase from $194 billion last year to $345-375
    billion by 2016, or $91 in drug spending per capita. The increase will be
    driven by rising incomes, continued low cost for drugs, and government-
    sponsored programs designed to increase access to treatments – by
    limiting patients’ exposure to costs and encouraging greater use of
    medicines. Generics and other products, including over-the-counter
    medicines, diagnostics and non-therapeutics, will account for approximately
    83 percent of the increase.

•   Pharma manufacturers will see minimal growth in their branded
    products through 2016. The market for branded medicines will
    experience flat to 3 percent annual growth through 2016 to $615-645
    billion, up from $596 billion in 2011. In the major developed markets,
    branded medicine growth will be severely constrained at only $10 billion
    over the five-year period due to patent expiries, increased cost-
    containment actions by payers and modest spending on newly launched
    products. The pharmerging markets are expected to contribute $25-30
    billion in branded product growth over the same period. Off-invoice
    discounts and rebates will offset about $5 billion of global branded medicine
    growth.

•   Manufacturers of small molecule generics will experience
    accelerating growth. Global generic spending is expected to increase
    from $242 billion in 2011 to $400-430 billion by 2016, fueled by volume
    growth in pharmerging markets and the ongoing transition to generics in
    developed nations. The impact of patent expiries primarily will be felt in the
    U.S. In Europe, limited savings from expiring patents are prompting policy
    shifts to encourage greater use of generics and lower reimbursement for
    these products.

•   Providers will have more treatment options due to additional new
    medicines being launched. Global launches for New Molecular Entities
    (NMEs) will rebound during the next five years, as 32-37 NMEs are
    expected to be launched per year through 2016. Between 2011-16,
4

          160-185 NMEs are expected to launch, compared with 142 between 2007-
          11. Innovative therapies to extend or improve patients’ quality of life are
          anticipated for treatment of Alzheimer’s, autoimmune diseases, diabetes,
          and a number of cancer and orphan diseases. Treatments for global priority
          diseases, such as malaria, tuberculosis and neglected diseases, are
          expected to improve, although gaps will remain.

      •   Biologics manufacturers will benefit from expanding market
          opportunity. Biologics are expected to account for about 17 percent of
          total global spending on medicines by 2016, as important clinical advances
          continue to emerge from research. Seven of the top ten global medicines
          by spending will be a biologic within five years. Adoption of biosimilars as
          low-cost alternatives to the original biologic medicines will remain limited,
          as biologics remain protected by patents or market exclusivity in many
          countries.



      The IMS Institute report, The Global Use of Medicines: Outlook through 2016,

including additional findings and details on methodology, is available at

www.theimsinstitute.org.

Analyses conducted for The Global Use of Medicines: Outlook through 2016 report
are based on IMS audits and include all types of biopharmaceuticals, including
biologics, OTC, and traditional medicines distributed and administered through
regulated delivery systems such as pharmacies, hospitals, clinics, physician offices,
and mail order, where applicable. Spending figures are derived from IMS Market
Prognosis™ and are reported at ex-manufacturer estimated prices that do not
reflect off-invoice discounts and rebates. IMS MIDAS™, Lifecycle™ R&D Focus,
Lifecycle™ New Product Focus, PharmaQuery™, Market Prognosis™ and Therapy
Forecaster™ were also used for assessing worldwide healthcare markets, therapy
class and product dynamics and country-level pricing and reimbursement
complexities. More detail on information sources is included in the report.
Developed markets are defined as the U.S., Japan, Top 5 Europe countries
(Germany, France, Italy, Spain, U.K.), Canada and South Korea. Pharmerging
countries are defined as those with greater than $1 billion in absolute spending
growth over 2012-16 and that have GDP per capita of less than $25,000 at
purchasing power parity: China, Brazil, India, Russia, Mexico, Turkey, Poland,
Venezuela, Argentina, Indonesia, South Africa, Thailand, Romania, Egypt, Ukraine,
Pakistan and Vietnam.
5

About the IMS Institute for Healthcare Informatics

      The IMS Institute for Healthcare Informatics provides key policy setters and

decision makers in the global health sector with unique and transformational

insights into healthcare dynamics derived from granular analysis of information. It

is a research-driven entity with a worldwide reach that collaborates with external

healthcare experts from across academia and the public and private sectors to

objectively apply IMS’s proprietary global information and analytical assets. More

information about the IMS Institute can be found at www.theimsinstitute.org.


About IMS Health

      IMS Health is a leading provider of information, services and technology for

the healthcare industry around the world. The company draws on its global

technology infrastructure and unique combination of in-depth, sophisticated

analytics, on-shore and off-shore commercial services, and software platforms to

help clients better understand the performance and dynamics of healthcare

systems. With a presence in 100+ countries and more than 55 years of industry

experience, IMS serves leading decision makers in healthcare, including

pharmaceutical manufacturers and distributors, providers, payers, government

agencies, policymakers, researchers and the financial community. Additional

information is available at www.imshealth.com.



                                        ###

Contenu connexe

En vedette

God we praise you
God we praise youGod we praise you
God we praise youLinnea Good
 
Amen siyakudumisa
Amen siyakudumisaAmen siyakudumisa
Amen siyakudumisaLinnea Good
 
Fantabulous food
Fantabulous foodFantabulous food
Fantabulous foodLinnea Good
 
Lord listen to your
Lord listen to yourLord listen to your
Lord listen to yourLinnea Good
 
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102acri009
 

En vedette (13)

For the beauty
For the beautyFor the beauty
For the beauty
 
Open our hearts
Open our heartsOpen our hearts
Open our hearts
 
God we praise you
God we praise youGod we praise you
God we praise you
 
Ucc creed
Ucc creedUcc creed
Ucc creed
 
Amen siyakudumisa
Amen siyakudumisaAmen siyakudumisa
Amen siyakudumisa
 
Fantabulous food
Fantabulous foodFantabulous food
Fantabulous food
 
Lord listen to your
Lord listen to yourLord listen to your
Lord listen to your
 
HSE24_Waeschetrends_092012.pdf
HSE24_Waeschetrends_092012.pdfHSE24_Waeschetrends_092012.pdf
HSE24_Waeschetrends_092012.pdf
 
In the bulb
In the bulbIn the bulb
In the bulb
 
2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf
 
Sanctuary
SanctuarySanctuary
Sanctuary
 
There is a balm
There is a balmThere is a balm
There is a balm
 
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102
הערות הקואליציה דב"ה להצעת וועדת הפנים בנושא דיור בהישג יד בתיקון 102
 

Plus de unn | UNITED NEWS NETWORK GmbH

Presseinformation Honda Modelle auf der Motorradwelt Boden….pdf
Presseinformation Honda Modelle auf der Motorradwelt Boden….pdfPresseinformation Honda Modelle auf der Motorradwelt Boden….pdf
Presseinformation Honda Modelle auf der Motorradwelt Boden….pdfunn | UNITED NEWS NETWORK GmbH
 
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdf
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdfVerkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdf
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdfunn | UNITED NEWS NETWORK GmbH
 
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdf
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdfPresseinformation Honda Neue Führerscheinregularien 18-01-….pdf
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdfunn | UNITED NEWS NETWORK GmbH
 

Plus de unn | UNITED NEWS NETWORK GmbH (20)

Über den Valentinstag.pdf
Über den Valentinstag.pdfÜber den Valentinstag.pdf
Über den Valentinstag.pdf
 
PM.pdf
PM.pdfPM.pdf
PM.pdf
 
130124_zoll_weltzolltag.pdf
130124_zoll_weltzolltag.pdf130124_zoll_weltzolltag.pdf
130124_zoll_weltzolltag.pdf
 
AL-KO Pressemeldung Vertragsverlaengerung FCA.pdf
AL-KO Pressemeldung Vertragsverlaengerung FCA.pdfAL-KO Pressemeldung Vertragsverlaengerung FCA.pdf
AL-KO Pressemeldung Vertragsverlaengerung FCA.pdf
 
Presseinformation Honda Modelle auf der Motorradwelt Boden….pdf
Presseinformation Honda Modelle auf der Motorradwelt Boden….pdfPresseinformation Honda Modelle auf der Motorradwelt Boden….pdf
Presseinformation Honda Modelle auf der Motorradwelt Boden….pdf
 
Presseinformation MSX125 auf den HMT 23-01-13.pdf
Presseinformation MSX125 auf den HMT 23-01-13.pdfPresseinformation MSX125 auf den HMT 23-01-13.pdf
Presseinformation MSX125 auf den HMT 23-01-13.pdf
 
130121RettedeinenNächstenRotary.pdf
130121RettedeinenNächstenRotary.pdf130121RettedeinenNächstenRotary.pdf
130121RettedeinenNächstenRotary.pdf
 
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdf
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdfVerkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdf
Verkostungen bei der ProWein 2013 Gemeinschaftsstand Pfalz.pdf
 
ZLB_PM_IsraellnachderWahl.pdf
ZLB_PM_IsraellnachderWahl.pdfZLB_PM_IsraellnachderWahl.pdf
ZLB_PM_IsraellnachderWahl.pdf
 
V.COM_PIAGET_MINUTE_REPEATER_DE-email.pdf
V.COM_PIAGET_MINUTE_REPEATER_DE-email.pdfV.COM_PIAGET_MINUTE_REPEATER_DE-email.pdf
V.COM_PIAGET_MINUTE_REPEATER_DE-email.pdf
 
V.COM_PIAGET_ALTIPLANO_SIHH_2013_DE-email.pdf
V.COM_PIAGET_ALTIPLANO_SIHH_2013_DE-email.pdfV.COM_PIAGET_ALTIPLANO_SIHH_2013_DE-email.pdf
V.COM_PIAGET_ALTIPLANO_SIHH_2013_DE-email.pdf
 
4549 - Pflanzenroller-Modellreihe.pdf
4549 - Pflanzenroller-Modellreihe.pdf4549 - Pflanzenroller-Modellreihe.pdf
4549 - Pflanzenroller-Modellreihe.pdf
 
Prinz_Charles_besucht_Halewood.pdf
Prinz_Charles_besucht_Halewood.pdfPrinz_Charles_besucht_Halewood.pdf
Prinz_Charles_besucht_Halewood.pdf
 
PI Daimler Mobility Services.pdf
PI Daimler Mobility Services.pdfPI Daimler Mobility Services.pdf
PI Daimler Mobility Services.pdf
 
PM.pdf
PM.pdfPM.pdf
PM.pdf
 
36_imm cologne_Schlussbericht.pdf
36_imm cologne_Schlussbericht.pdf36_imm cologne_Schlussbericht.pdf
36_imm cologne_Schlussbericht.pdf
 
01-21-AI-Graziano.pdf
01-21-AI-Graziano.pdf01-21-AI-Graziano.pdf
01-21-AI-Graziano.pdf
 
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdf
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdfPresseinformation Honda Neue Führerscheinregularien 18-01-….pdf
Presseinformation Honda Neue Führerscheinregularien 18-01-….pdf
 
Text EÖ-PK 2013 .pdf
Text EÖ-PK 2013 .pdfText EÖ-PK 2013 .pdf
Text EÖ-PK 2013 .pdf
 
PM4 INVENTA Garden.pdf
PM4 INVENTA Garden.pdfPM4 INVENTA Garden.pdf
PM4 INVENTA Garden.pdf
 

FINAL - IMS Global Use of Medicines Press Release.pdf

  • 1. News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly $1.2 Trillion By 2016 Spending in Pharmerging Markets to Nearly Double while Health Systems in Developed Countries Benefit from Historically Low Spending Growth PARSIPPANY, NJ, July 12, 2012 – Following several years of slowing growth, the global market for medicines is poised to rebound from an expected low point of 3-4 percent growth in 2012 to 5-7 percent in 2016, according to a new forecast issued by the IMS Institute for Healthcare Informatics. The report, The Global Use of Medicines: Outlook through 2016, found that annual global spending on medicines will rise from $956 billion in 2011 to nearly $1.2 trillion in 2016, representing a compound annual growth rate of 3-6 percent. Growth in annual global spending is forecast to more than double by 2016 to as much as $70 billion, up from a $30 billion pace this year, driven by volume increases in the pharmerging markets and an uptick in spending in developed nations. Additionally, patent expiries, which will peak in 2012, as well as increased cost-containment actions by payers, will constrain branded medicine spending growth through 2016, at 0-3 percent. Developed markets are expected to
  • 2. 2 experience their lowest annual growth this year, at less than 1 percent or $3 billion, and then rebound to $18-20 billion in annual growth in the 2014-16 period. “As health systems around the world grapple with macroeconomic pressures and the demand for expanded access and improved outcomes, medicines will play an even more vital role in patient care over the next five years,” says Murray Aitken, executive director, IMS Institute for Healthcare Informatics. “The trillion- dollar spending on medicines we forecast for 2016 represents a rebound in growth that will accentuate the challenges of access and affordability facing those who consume and pay for healthcare around the world.” In its latest analysis, the IMS Institute identifies the following dynamics: • Health systems in developed economies will experience slow growth in medicine spending. Spending on medicines in developed nations will increase by a total of $60-70 billion from 2011 to 2016, following an increase of $104 billion between 2006 and 2011. Despite the highest number of patent expiries in history, spending in the U.S. will grow by $35-45 billion over the next five years, representing an average annual growth rate of 1-4 percent, as newer medicines that address unmet needs are introduced and patient access expands in 2014 due to implementation of the Affordable Care Act. In Europe, growth will be in the -1 to 2 percent range due to significant austerity programs and healthcare cost-containment initiatives. The Japanese market for medicines is forecast to grow 1-4 percent annually through 2016, slightly lower than the rate during the prior five years and reflecting biennial price cuts scheduled for 2012, 2014 and 2016. Overall, patent expiries in developed markets will yield a five-year “patent dividend” of $106 billion, reflecting reduced brand spending of $127 billion offset by $21 billion in higher generics spending.
  • 3. 3 • Health systems in pharmerging markets will nearly double their medicine spending in five years. Annual spending on medicines in the pharmerging markets will increase from $194 billion last year to $345-375 billion by 2016, or $91 in drug spending per capita. The increase will be driven by rising incomes, continued low cost for drugs, and government- sponsored programs designed to increase access to treatments – by limiting patients’ exposure to costs and encouraging greater use of medicines. Generics and other products, including over-the-counter medicines, diagnostics and non-therapeutics, will account for approximately 83 percent of the increase. • Pharma manufacturers will see minimal growth in their branded products through 2016. The market for branded medicines will experience flat to 3 percent annual growth through 2016 to $615-645 billion, up from $596 billion in 2011. In the major developed markets, branded medicine growth will be severely constrained at only $10 billion over the five-year period due to patent expiries, increased cost- containment actions by payers and modest spending on newly launched products. The pharmerging markets are expected to contribute $25-30 billion in branded product growth over the same period. Off-invoice discounts and rebates will offset about $5 billion of global branded medicine growth. • Manufacturers of small molecule generics will experience accelerating growth. Global generic spending is expected to increase from $242 billion in 2011 to $400-430 billion by 2016, fueled by volume growth in pharmerging markets and the ongoing transition to generics in developed nations. The impact of patent expiries primarily will be felt in the U.S. In Europe, limited savings from expiring patents are prompting policy shifts to encourage greater use of generics and lower reimbursement for these products. • Providers will have more treatment options due to additional new medicines being launched. Global launches for New Molecular Entities (NMEs) will rebound during the next five years, as 32-37 NMEs are expected to be launched per year through 2016. Between 2011-16,
  • 4. 4 160-185 NMEs are expected to launch, compared with 142 between 2007- 11. Innovative therapies to extend or improve patients’ quality of life are anticipated for treatment of Alzheimer’s, autoimmune diseases, diabetes, and a number of cancer and orphan diseases. Treatments for global priority diseases, such as malaria, tuberculosis and neglected diseases, are expected to improve, although gaps will remain. • Biologics manufacturers will benefit from expanding market opportunity. Biologics are expected to account for about 17 percent of total global spending on medicines by 2016, as important clinical advances continue to emerge from research. Seven of the top ten global medicines by spending will be a biologic within five years. Adoption of biosimilars as low-cost alternatives to the original biologic medicines will remain limited, as biologics remain protected by patents or market exclusivity in many countries. The IMS Institute report, The Global Use of Medicines: Outlook through 2016, including additional findings and details on methodology, is available at www.theimsinstitute.org. Analyses conducted for The Global Use of Medicines: Outlook through 2016 report are based on IMS audits and include all types of biopharmaceuticals, including biologics, OTC, and traditional medicines distributed and administered through regulated delivery systems such as pharmacies, hospitals, clinics, physician offices, and mail order, where applicable. Spending figures are derived from IMS Market Prognosis™ and are reported at ex-manufacturer estimated prices that do not reflect off-invoice discounts and rebates. IMS MIDAS™, Lifecycle™ R&D Focus, Lifecycle™ New Product Focus, PharmaQuery™, Market Prognosis™ and Therapy Forecaster™ were also used for assessing worldwide healthcare markets, therapy class and product dynamics and country-level pricing and reimbursement complexities. More detail on information sources is included in the report. Developed markets are defined as the U.S., Japan, Top 5 Europe countries (Germany, France, Italy, Spain, U.K.), Canada and South Korea. Pharmerging countries are defined as those with greater than $1 billion in absolute spending growth over 2012-16 and that have GDP per capita of less than $25,000 at purchasing power parity: China, Brazil, India, Russia, Mexico, Turkey, Poland, Venezuela, Argentina, Indonesia, South Africa, Thailand, Romania, Egypt, Ukraine, Pakistan and Vietnam.
  • 5. 5 About the IMS Institute for Healthcare Informatics The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to objectively apply IMS’s proprietary global information and analytical assets. More information about the IMS Institute can be found at www.theimsinstitute.org. About IMS Health IMS Health is a leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and software platforms to help clients better understand the performance and dynamics of healthcare systems. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at www.imshealth.com. ###